Sio Gene Therapies to Present at the 10th Annual SVB Leerink Global Healthcare Conference
Sio Gene Therapies Inc. (NASDAQ: SIOX), focused on gene therapies for neurodegenerative diseases, will present at the 10th Annual SVB Leerink Global Healthcare Conference from February 22-26, 2021. The presentation is scheduled for February 24, 2021, at 1:40 PM ET, featuring CEO Pavan Cheruvu in a fireside chat format. Additionally, the company management will engage in one-on-one investor meetings during the event. Sio Gene Therapies aims to develop potentially curative therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff diseases, while also targeting prevalent conditions like Parkinson's disease.
- None.
- None.
NEW YORK and RESEARCH TRIANGLE PARK, N.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company will present at the 10th Annual SVB Leerink Global Healthcare Conference taking place February 22-26, 2021. Details on the presentation can be found below.
| Date: | Wednesday, February 24, 2021 |
| Time: | 1:40 PM ET |
| Participation Format: Presenter: | Fireside chat Pavan Cheruvu, MD, Chief Executive Officer |
Company management will also participate in one-on-one investor meetings at the conference.
About Sio Gene Therapies
Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients. Our current pipeline of clinical-stage candidates includes the first potentially curative AAV-based gene therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff diseases, which are rare and uniformly fatal pediatric conditions caused by single gene deficiencies. We are also expanding the reach of gene therapy to highly prevalent conditions such as Parkinson’s disease, which affects millions of patients globally. Led by an experienced team of gene therapy development experts, and supported by collaborations with premier academic, industry and patient advocacy organizations, Sio is focused on accelerating its candidates through clinical trials to liberate patients with debilitating diseases through the transformational power of gene therapies. For more information, visit www.siogtx.com.
Contacts:
Media
Josephine Belluardo, Ph.D.
LifeSci Communications
(646) 751-4361
jo@lifescicomms.com
info@siogtx.com
Investors and Analysts
Parag V. Meswani, Pharm.D.
Sio Gene Therapies Inc.
Chief Commercial Officer
investors@siogtx.com
FAQ
What is the date of Sio Gene Therapies' presentation at the SVB Leerink Global Healthcare Conference?
What time will Sio Gene Therapies' presentation occur at the conference?
Who will present for Sio Gene Therapies at the SVB Leerink Global Healthcare Conference?
What is Sio Gene Therapies focusing on in their pipeline?
Will Sio Gene Therapies participate in one-on-one investor meetings?
